Versartis Inc (VSAR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Versartis Inc (VSAR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7607
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Versartis Inc (Versartis) is a biopharmaceutical company that develops, manufactures and commercializes medicines for the treatment of endocrine disorders. The company’s lead product candidate include somavaratan (VRS-317) is a recombinant human growth hormone (GHD) that is designed to reduce the burden of daily injection therapy which is used in the treatment of growth hormone deficiency in both children and adults. It utilizes half-life extension technology, a proprietary recombinant polypeptide technology for development of its products. The company serves life science industry. Versartis is headquartered in Menlo Park, California, the US.

Versartis Inc (VSAR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Versartis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Versartis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Versartis Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Versartis Raises US$55 Million In Series E Financing 10
Versartis Secures USD12.49 Million in Series C Venture Funding 12
Versartis Raises US$20 Million In Series D Financing 13
Versartis Raises US$25 Million In Series C Financing 15
Licensing Agreements 17
Teijin Pharma Enters into Licensing Agreement with Versartis 17
Equity Offering 19
Versartis Raises USD63.4 Million in Public Offering of Shares 19
Versartis Raises USD86.3 Million in Public Offering of Shares 21
Versartis Completes IPO Of For US$145 Million 23
Versartis Inc – Key Competitors 25
Versartis Inc – Key Employees 26
Versartis Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Aug 07, 2018: Versartis announces second quarter 2018 financial results 28
May 08, 2018: Versartis Reports First Quarter 2018 Financial Results 30
Mar 01, 2018: Versartis Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 31
Oct 26, 2017: Versartis Reports Third Quarter 2017 Financial Results and Provides Corporate Update 33
Jul 27, 2017: Versartis Reports Second Quarter 2017 Financial Results 34
Apr 27, 2017: Versartis Reports First Quarter 2017 Financial Results 36
Feb 21, 2017: Versartis Reports Fourth Quarter 2016 Financial Results 37
Corporate Communications 39
Sep 05, 2017: Versartis Announces Expansion of Executive Leadership Team with Addition of Dr. Robert Gut as the Head of Global Clinical, Medical and Regulatory Affairs 39
Jun 01, 2017: Versartis Appoints Eric Dobmeier to Board of Directors 40
Apr 25, 2017: Versartis Appoints Jay Stout, Ph.D., as Senior Vice President, Technical Operations 41
Mar 15, 2017: Versartis Appoints Tracy Woody as Chief Commercial Officer 42
Jan 31, 2017: Versartis announces management changes 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Versartis Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Versartis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Versartis Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Versartis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Versartis Raises US$55 Million In Series E Financing 10
Versartis Secures USD12.49 Million in Series C Venture Funding 12
Versartis Raises US$20 Million In Series D Financing 13
Versartis Raises US$25 Million In Series C Financing 15
Teijin Pharma Enters into Licensing Agreement with Versartis 17
Versartis Raises USD63.4 Million in Public Offering of Shares 19
Versartis Raises USD86.3 Million in Public Offering of Shares 21
Versartis Completes IPO Of For US$145 Million 23
Versartis Inc, Key Competitors 25
Versartis Inc, Key Employees 26
Versartis Inc, Subsidiaries 27

List of Figures
Versartis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Versartis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Versartis Inc (VSAR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • OraSure Technologies Inc (OSUR):医療機器:M&Aディール及び事業提携情報
    Summary OraSure Technologies Inc (OraSure) is a manufacturer and distributor of oral fluid specimen collection devices, diagnostic products and other medical devices. Its product portfolio encompasses infectious disease tests for the detection of antibodies for the HIV and Hepatitis C virus; Ebola v …
  • Cesca Therapeutics Inc (KOOL):企業の財務・戦略的SWOT分析
    Cesca Therapeutics Inc (KOOL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Industrial Bank Of Korea:企業の戦略・SWOT・財務分析
    Industrial Bank Of Korea - Strategy, SWOT and Corporate Finance Report Summary Industrial Bank Of Korea - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Delaware Municipal Electric Corporation, Inc.:企業の戦略的SWOT分析
    Delaware Municipal Electric Corporation, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors …
  • Audentes Therapeutics Inc (BOLD):企業の財務・戦略的SWOT分析
    Summary Audentes Therapeutics Inc (Audentes) is a biotechnology company that focuses on the development and commercialization of gene therapy products for rare diseases. The company’s pipeline products include AT132, intended for the treatment of X-linked myotubular myopathy; AT982, for the treatmen …
  • Payton Planar Magnetics Ltd (PAY):企業の財務・戦略的SWOT分析
    Payton Planar Magnetics Ltd (PAY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Universal Display Corp (OLED):企業の財務・戦略的SWOT分析
    Summary Universal Display Corp (UDC) is a clean technology company that conducts research, develops and markets organic light emitting diode, technologies and materials. The company offers PHOLED materials which are used in making OLED displays and lighting panels. It provides technologies such as F …
  • KornFerry International (KFY):企業の財務・戦略的SWOT分析
    KornFerry International (KFY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Plexxikon Inc-製薬・医療分野:企業M&A・提携分析
    Summary Plexxikon Inc (Plexxikon), a subsidiary of Daiichi Sankyo Company Ltd is a drug discovery company that concentrates on discovery and development of novel, small molecules. The company’s pipeline products include PLX3397 to treat adjuvant glioblastoma, neoadjuvant breast, melanoma and solid t …
  • Tainergy Tech Co Ltd (4934):電力:M&Aディール及び事業提携情報
    Summary Tainergy Tech Co Ltd (Tainergy) is a renewable energy company that designs, develops, manufactures and markets solar energy products. The company provides products such as solar deionized water systems, multi-crystalline silicon solar cell, standard solar modules, solar module with build in …
  • Duke Energy Indiana LLC:企業の戦略的SWOT分析
    Duke Energy Indiana LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • American Rheinmetall Munitions, Inc.:企業の戦略・SWOT・財務情報
    American Rheinmetall Munitions, Inc. - Strategy, SWOT and Corporate Finance Report Summary American Rheinmetall Munitions, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • SeraCare Life Sciences Inc:企業の戦略的SWOT分析
    SeraCare Life Sciences Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Romark Laboratories LC:製薬・医療:M&Aディール及び事業提携情報
    Summary Romark Laboratories LC (Romark Laboratories) is a pharmaceutical company that discovers, develops and commercializes small molecules for the treatment of infectious diseases and cancers. The company develops Nitazoxanide, an oral suspension and tablets used for the treatment of intestinal pa …
  • Telenor ASA:企業の戦略・SWOT・財務情報
    Telenor ASA - Strategy, SWOT and Corporate Finance Report Summary Telenor ASA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Groupe Guillin SA:企業の戦略・SWOT・財務情報
    Groupe Guillin SA - Strategy, SWOT and Corporate Finance Report Summary Groupe Guillin SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Symphogen AS-製薬・医療分野:企業M&A・提携分析
    Summary Symphogen A/S (Symphogen) is a biopharmaceutical company that specializes in the field of recombinant antibody mixtures for therapeutic use in cancer. The company focuses on developing superior monoclonal antibody (mAb) mixture therapeutics to enhance the lives of patients with cancer and ot …
  • KARL STORZ SE & Co KG:企業の戦略的SWOT分析
    KARL STORZ SE & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Rexel S.A.:戦略・SWOT・企業財務分析
    Rexel S.A. - Strategy, SWOT and Corporate Finance Report Summary Rexel S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Electricidade de Mocambique EP:電力:M&Aディール及び事業提携情報
    Summary Electricidade de Mocambique EP (EDM) is a state owned vertically integrated energy utility that generates, distributes, transmits, and commercializes electricity. It produces electricity from hydro and thermal sources. The company has interests in Lichinga, Cuamba, Corumana, Chicamba, and Ma …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆